^
    Back
    Association details:
    Biomarker:COX7A2L-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Zykadia (ceritinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Zhongguo Fei Ai Za Zhi
    Title:

    [Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma with COX7A2L-ALK Fusion: A Case Report and Literature Review]

    Published date:
    04/20/2023
    Excerpt:
    A case of advanced lung adenocarcinoma with rare COX7A2L-ALK (C2:A20) fusion detected by NGS was reported in Peking Union Medical College Hospital...The best response of the patient was assessed as partial response (PR) with Ceritinib treatment.
    DOI:
    10.3779/j.issn.1009-3419.2023.102.15